The European Commission has granted authorisations for uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (‘4-tert-OPnEO’):

• One use applied for by Yposkesi (4 January 2028);
• One use applied for by Rousselot bvba (4 January 2033);
• One use applied for by Takeda Manufacturing Austria AG (4 January 2033);
• One use applied for by Baxalta Belgium Manufacturing SA (4 January 2033);
• Two uses applied for by Wallac Oy (4 January 2026); and
• Two uses applied for by Pfizer Ireland Pharmaceuticals (4 January 2033, 4 January 2028)